Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met ...

Johnson & Johnson: FDA approval of ICOTYDE (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill ICOTYDE ...

J&J wins FDA nod for plaque psoriasis pill developed with Protagonist

Johnson & Johnson (JNJ) on Wednesday announced that the U.S. Food and Drug Administration (FDA) approved Icotyde, a once-daily pill developed with Protagonist Therapeutics (PTGX), as a treatment for ...
NEXTpittsburgh

12+ things to do this weekend, from NatureFest to the Pittsburgh Fringe Festival

Find all the best things to do in Pittsburgh this weekend, from NatureFest to the Pittsburgh Fringe Festival to the Japanese Film Festival.

Major UK airline plunges into administration - in business since 1997

They operated in the UK, Ireland, and Europe.